Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Article Swipe

PDF

Matteo Dugo , Chiun‐Sheng Huang , Daniel Egle , Begoña Bermejo , C. Zamagni , Robert S. Seitz , Tyler J. Nielsen , Marc Thill , Antonio Antón , Stefania Russo , Eva Ciruelos , Brock L. Schweitzer , Douglas Teller Ross , Barbara Galbardi , Richard Greil , Semiglazov Vf , Balázs Győrffy , Marco Colleoni , Catherine M. Kelly , Gabriella Mariani , Lucia Del Mastro , Olivia Blasi , Maurizio Callari , Lajos Pusztai , Pinuccia Valagussa , Giuseppe Viale , Luca Gianni , Giampaolo Bianchini ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.27434263

Supplementary Figure 4. Baseline RNA-Seq IO score. A) Frequency of IO+ and IO− patients in the overall NeoTRIP population (left) and by treatment arm (right); B) Association between IO classes and PD-L1 status (left) or sTILs (right); C) pCR rate by IO classification and treatment arm. P-values by logistic regression. D) Distribution of continuous IO score by treatment arm and pCR status. P-values by logistic regression. E) Akaike information criterion (AIC) from univariate logistic regression models obtained using categorical RT-qPCR or RNA-Seq IO scores by treatment arm. Analyses were performed on patients with matched RT-qPCR and RNA-Seq data.

Related Topics

Atezolizumab

Triple-Negative Breast Cancer

Concepts

Atezolizumab Triple-negative breast cancer Breast cancer Oncology Signature (topology) Gene signature Chemotherapy Medicine Immune system Internal medicine Gene Cancer research Cancer Biology Immunotherapy Immunology Gene expression Genetics Mathematics Pembrolizumab Geometry

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/1078-0432.27434263
PDF: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434263/1/files/50134549.pdf
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4403988526

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4403988526

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.27434263

Digital Object Identifier
Title: Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2024

Year of publication
Publication date: 2024-11-01

Full publication date if available
Authors: Matteo Dugo, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, C. Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Antón, Stefania Russo, Eva Ciruelos, Brock L. Schweitzer, Douglas Teller Ross, Barbara Galbardi, Richard Greil, Semiglazov Vf, Balázs Győrffy, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Blasi, Maurizio Callari, Lajos Pusztai, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.27434263

Publisher landing page
PDF URL: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434263/1/files/50134549.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434263/1/files/50134549.pdf

Direct OA link when available
Concepts: Atezolizumab, Triple-negative breast cancer, Breast cancer, Oncology, Signature (topology), Gene signature, Chemotherapy, Medicine, Immune system, Internal medicine, Gene, Cancer research, Cancer, Biology, Immunotherapy, Immunology, Gene expression, Genetics, Mathematics, Pembrolizumab, Geometry

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4403988526
doi	https://doi.org/10.1158/1078-0432.27434263
ids.doi	https://doi.org/10.1158/1078-0432.27434263
ids.openalex	https://openalex.org/W4403988526
fwci	0.0
type	preprint
title	Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T10158
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9986000061035156
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2730
topics[0].subfield.display_name	Oncology
topics[0].display_name	Cancer Immunotherapy and Biomarkers
topics[1].id	https://openalex.org/T10580
topics[1].field.id	https://openalex.org/fields/24
topics[1].field.display_name	Immunology and Microbiology
topics[1].score	0.9764000177383423
topics[1].domain.id	https://openalex.org/domains/1
topics[1].domain.display_name	Life Sciences
topics[1].subfield.id	https://openalex.org/subfields/2403
topics[1].subfield.display_name	Immunology
topics[1].display_name	Immunotherapy and Immune Responses
topics[2].id	https://openalex.org/T11491
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9556999802589417
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2730
topics[2].subfield.display_name	Oncology
topics[2].display_name	CAR-T cell therapy research
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2775949291
concepts[0].level	5
concepts[0].score	0.9640744924545288
concepts[0].wikidata	https://www.wikidata.org/wiki/Q20707748
concepts[0].display_name	Atezolizumab
concepts[1].id	https://openalex.org/C2780110267
concepts[1].level	4
concepts[1].score	0.8220731019973755
concepts[1].wikidata	https://www.wikidata.org/wiki/Q7843332
concepts[1].display_name	Triple-negative breast cancer
concepts[2].id	https://openalex.org/C530470458
concepts[2].level	3
concepts[2].score	0.6850903034210205
concepts[2].wikidata	https://www.wikidata.org/wiki/Q128581
concepts[2].display_name	Breast cancer
concepts[3].id	https://openalex.org/C143998085
concepts[3].level	1
concepts[3].score	0.6069053411483765
concepts[3].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[3].display_name	Oncology
concepts[4].id	https://openalex.org/C2779696439
concepts[4].level	2
concepts[4].score	0.5774462819099426
concepts[4].wikidata	https://www.wikidata.org/wiki/Q7512811
concepts[4].display_name	Signature (topology)
concepts[5].id	https://openalex.org/C2779733811
concepts[5].level	4
concepts[5].score	0.5115300416946411
concepts[5].wikidata	https://www.wikidata.org/wiki/Q5531562
concepts[5].display_name	Gene signature
concepts[6].id	https://openalex.org/C2776694085
concepts[6].level	2
concepts[6].score	0.4973490536212921
concepts[6].wikidata	https://www.wikidata.org/wiki/Q974135
concepts[6].display_name	Chemotherapy
concepts[7].id	https://openalex.org/C71924100
concepts[7].level	0
concepts[7].score	0.47104692459106445
concepts[7].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[7].display_name	Medicine
concepts[8].id	https://openalex.org/C8891405
concepts[8].level	2
concepts[8].score	0.4528915286064148
concepts[8].wikidata	https://www.wikidata.org/wiki/Q1059
concepts[8].display_name	Immune system
concepts[9].id	https://openalex.org/C126322002
concepts[9].level	1
concepts[9].score	0.4478680193424225
concepts[9].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[9].display_name	Internal medicine
concepts[10].id	https://openalex.org/C104317684
concepts[10].level	2
concepts[10].score	0.3702305257320404
concepts[10].wikidata	https://www.wikidata.org/wiki/Q7187
concepts[10].display_name	Gene
concepts[11].id	https://openalex.org/C502942594
concepts[11].level	1
concepts[11].score	0.33875077962875366
concepts[11].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[11].display_name	Cancer research
concepts[12].id	https://openalex.org/C121608353
concepts[12].level	2
concepts[12].score	0.32817673683166504
concepts[12].wikidata	https://www.wikidata.org/wiki/Q12078
concepts[12].display_name	Cancer
concepts[13].id	https://openalex.org/C86803240
concepts[13].level	0
concepts[13].score	0.25109997391700745
concepts[13].wikidata	https://www.wikidata.org/wiki/Q420
concepts[13].display_name	Biology
concepts[14].id	https://openalex.org/C2777701055
concepts[14].level	3
concepts[14].score	0.2181777060031891
concepts[14].wikidata	https://www.wikidata.org/wiki/Q1427096
concepts[14].display_name	Immunotherapy
concepts[15].id	https://openalex.org/C203014093
concepts[15].level	1
concepts[15].score	0.21559786796569824
concepts[15].wikidata	https://www.wikidata.org/wiki/Q101929
concepts[15].display_name	Immunology
concepts[16].id	https://openalex.org/C150194340
concepts[16].level	3
concepts[16].score	0.14497625827789307
concepts[16].wikidata	https://www.wikidata.org/wiki/Q26972
concepts[16].display_name	Gene expression
concepts[17].id	https://openalex.org/C54355233
concepts[17].level	1
concepts[17].score	0.1264883577823639
concepts[17].wikidata	https://www.wikidata.org/wiki/Q7162
concepts[17].display_name	Genetics
concepts[18].id	https://openalex.org/C33923547
concepts[18].level	0
concepts[18].score	0.08116656541824341
concepts[18].wikidata	https://www.wikidata.org/wiki/Q395
concepts[18].display_name	Mathematics
concepts[19].id	https://openalex.org/C2780057760
concepts[19].level	4
concepts[19].score	0.05108574032783508
concepts[19].wikidata	https://www.wikidata.org/wiki/Q13896859
concepts[19].display_name	Pembrolizumab
concepts[20].id	https://openalex.org/C2524010
concepts[20].level	1
concepts[20].score	0.0
concepts[20].wikidata	https://www.wikidata.org/wiki/Q8087
concepts[20].display_name	Geometry
keywords[0].id	https://openalex.org/keywords/atezolizumab
keywords[0].score	0.9640744924545288
keywords[0].display_name	Atezolizumab
keywords[1].id	https://openalex.org/keywords/triple-negative-breast-cancer
keywords[1].score	0.8220731019973755
keywords[1].display_name	Triple-negative breast cancer
keywords[2].id	https://openalex.org/keywords/breast-cancer
keywords[2].score	0.6850903034210205
keywords[2].display_name	Breast cancer
keywords[3].id	https://openalex.org/keywords/oncology
keywords[3].score	0.6069053411483765
keywords[3].display_name	Oncology
keywords[4].id	https://openalex.org/keywords/signature
keywords[4].score	0.5774462819099426
keywords[4].display_name	Signature (topology)
keywords[5].id	https://openalex.org/keywords/gene-signature
keywords[5].score	0.5115300416946411
keywords[5].display_name	Gene signature
keywords[6].id	https://openalex.org/keywords/chemotherapy
keywords[6].score	0.4973490536212921
keywords[6].display_name	Chemotherapy
keywords[7].id	https://openalex.org/keywords/medicine
keywords[7].score	0.47104692459106445
keywords[7].display_name	Medicine
keywords[8].id	https://openalex.org/keywords/immune-system
keywords[8].score	0.4528915286064148
keywords[8].display_name	Immune system
keywords[9].id	https://openalex.org/keywords/internal-medicine
keywords[9].score	0.4478680193424225
keywords[9].display_name	Internal medicine
keywords[10].id	https://openalex.org/keywords/gene
keywords[10].score	0.3702305257320404
keywords[10].display_name	Gene
keywords[11].id	https://openalex.org/keywords/cancer-research
keywords[11].score	0.33875077962875366
keywords[11].display_name	Cancer research
keywords[12].id	https://openalex.org/keywords/cancer
keywords[12].score	0.32817673683166504
keywords[12].display_name	Cancer
keywords[13].id	https://openalex.org/keywords/biology
keywords[13].score	0.25109997391700745
keywords[13].display_name	Biology
keywords[14].id	https://openalex.org/keywords/immunotherapy
keywords[14].score	0.2181777060031891
keywords[14].display_name	Immunotherapy
keywords[15].id	https://openalex.org/keywords/immunology
keywords[15].score	0.21559786796569824
keywords[15].display_name	Immunology
keywords[16].id	https://openalex.org/keywords/gene-expression
keywords[16].score	0.14497625827789307
keywords[16].display_name	Gene expression
keywords[17].id	https://openalex.org/keywords/genetics
keywords[17].score	0.1264883577823639
keywords[17].display_name	Genetics
keywords[18].id	https://openalex.org/keywords/mathematics
keywords[18].score	0.08116656541824341
keywords[18].display_name	Mathematics
keywords[19].id	https://openalex.org/keywords/pembrolizumab
keywords[19].score	0.05108574032783508
keywords[19].display_name	Pembrolizumab
language	en
locations[0].id	doi:10.1158/1078-0432.27434263
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434263/1/files/50134549.pdf
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.27434263
locations[1].id	pmh:oai:figshare.com:article/27434263
locations[1].is_oa	True
locations[1].source.id	https://openalex.org/S4306400572
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	OPAL (Open@LaTrobe) (La Trobe University)
locations[1].source.host_organization	https://openalex.org/I196829312
locations[1].source.host_organization_name	La Trobe University
locations[1].source.host_organization_lineage	https://openalex.org/I196829312
locations[1].license	cc-by
locations[1].pdf_url
locations[1].version	submittedVersion
locations[1].raw_type	Text
locations[1].license_id	https://openalex.org/licenses/cc-by
locations[1].is_accepted	False
locations[1].is_published	False
locations[1].raw_source_name
locations[1].landing_page_url	https://figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434263
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5063636724
authorships[0].author.orcid	https://orcid.org/0000-0001-9786-2763
authorships[0].author.display_name	Matteo Dugo
authorships[0].author_position	first
authorships[0].raw_author_name	Matteo Dugo
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5027981189
authorships[1].author.orcid	https://orcid.org/0000-0002-6557-211X
authorships[1].author.display_name	Chiun‐Sheng Huang
authorships[1].author_position	middle
authorships[1].raw_author_name	Chiun-Sheng Huang
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5049254392
authorships[2].author.orcid	https://orcid.org/0000-0003-0283-8176
authorships[2].author.display_name	Daniel Egle
authorships[2].author_position	middle
authorships[2].raw_author_name	Daniel Egle
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5018922989
authorships[3].author.orcid	https://orcid.org/0000-0001-7773-5994
authorships[3].author.display_name	Begoña Bermejo
authorships[3].author_position	middle
authorships[3].raw_author_name	Begoña Bermejo
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5021445195
authorships[4].author.orcid	https://orcid.org/0000-0002-7143-9091
authorships[4].author.display_name	C. Zamagni
authorships[4].author_position	middle
authorships[4].raw_author_name	Claudio Zamagni
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5033135467
authorships[5].author.orcid	https://orcid.org/0000-0002-5806-2840
authorships[5].author.display_name	Robert S. Seitz
authorships[5].author_position	middle
authorships[5].raw_author_name	Robert S. Seitz
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5050750573
authorships[6].author.orcid	https://orcid.org/0000-0002-9576-2838
authorships[6].author.display_name	Tyler J. Nielsen
authorships[6].author_position	middle
authorships[6].raw_author_name	Tyler J. Nielsen
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5055136263
authorships[7].author.orcid	https://orcid.org/0000-0002-8800-8044
authorships[7].author.display_name	Marc Thill
authorships[7].author_position	middle
authorships[7].raw_author_name	Marc Thill
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5090790623
authorships[8].author.orcid	https://orcid.org/0000-0002-2802-6232
authorships[8].author.display_name	Antonio Antón
authorships[8].author_position	middle
authorships[8].raw_author_name	Antonio Antón-Torres
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5048548720
authorships[9].author.orcid
authorships[9].author.display_name	Stefania Russo
authorships[9].author_position	middle
authorships[9].raw_author_name	Stefania Russo
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5077805370
authorships[10].author.orcid	https://orcid.org/0000-0002-2796-1042
authorships[10].author.display_name	Eva Ciruelos
authorships[10].author_position	middle
authorships[10].raw_author_name	Eva Maria Ciruelos
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5010230522
authorships[11].author.orcid	https://orcid.org/0000-0003-0178-5594
authorships[11].author.display_name	Brock L. Schweitzer
authorships[11].author_position	middle
authorships[11].raw_author_name	Brock L. Schweitzer
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5008822450
authorships[12].author.orcid
authorships[12].author.display_name	Douglas Teller Ross
authorships[12].author_position	middle
authorships[12].raw_author_name	Douglas T. Ross
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5029069852
authorships[13].author.orcid	https://orcid.org/0000-0003-1424-421X
authorships[13].author.display_name	Barbara Galbardi
authorships[13].author_position	middle
authorships[13].raw_author_name	Barbara Galbardi
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5039994927
authorships[14].author.orcid	https://orcid.org/0000-0002-4462-3694
authorships[14].author.display_name	Richard Greil
authorships[14].author_position	middle
authorships[14].raw_author_name	Richard Greil
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5068100907
authorships[15].author.orcid	https://orcid.org/0000-0003-0077-9619
authorships[15].author.display_name	Semiglazov Vf
authorships[15].author_position	middle
authorships[15].raw_author_name	Vladimir Semiglazov
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5023340072
authorships[16].author.orcid
authorships[16].author.display_name	Balázs Győrffy
authorships[16].author_position	middle
authorships[16].raw_author_name	Balázs Gyorffy
authorships[16].is_corresponding	False
authorships[17].author.id	https://openalex.org/A5053376791
authorships[17].author.orcid	https://orcid.org/0000-0002-5743-3013
authorships[17].author.display_name	Marco Colleoni
authorships[17].author_position	middle
authorships[17].raw_author_name	Marco Colleoni
authorships[17].is_corresponding	False
authorships[18].author.id	https://openalex.org/A5076556096
authorships[18].author.orcid	https://orcid.org/0000-0001-8355-6714
authorships[18].author.display_name	Catherine M. Kelly
authorships[18].author_position	middle
authorships[18].raw_author_name	Catherine M. Kelly
authorships[18].is_corresponding	False
authorships[19].author.id	https://openalex.org/A5081344507
authorships[19].author.orcid	https://orcid.org/0000-0001-7733-3143
authorships[19].author.display_name	Gabriella Mariani
authorships[19].author_position	middle
authorships[19].raw_author_name	Gabriella Mariani
authorships[19].is_corresponding	False
authorships[20].author.id	https://openalex.org/A5074479074
authorships[20].author.orcid	https://orcid.org/0000-0002-9546-5841
authorships[20].author.display_name	Lucia Del Mastro
authorships[20].author_position	middle
authorships[20].raw_author_name	Lucia Del Mastro
authorships[20].is_corresponding	False
authorships[21].author.id	https://openalex.org/A5107490983
authorships[21].author.orcid
authorships[21].author.display_name	Olivia Blasi
authorships[21].author_position	middle
authorships[21].raw_author_name	Olivia Blasi
authorships[21].is_corresponding	False
authorships[22].author.id	https://openalex.org/A5040640445
authorships[22].author.orcid	https://orcid.org/0000-0001-5239-0918
authorships[22].author.display_name	Maurizio Callari
authorships[22].author_position	middle
authorships[22].raw_author_name	Maurizio Callari
authorships[22].is_corresponding	False
authorships[23].author.id	https://openalex.org/A5021113979
authorships[23].author.orcid	https://orcid.org/0000-0001-9632-6686
authorships[23].author.display_name	Lajos Pusztai
authorships[23].author_position	middle
authorships[23].raw_author_name	Lajos Pusztai
authorships[23].is_corresponding	False
authorships[24].author.id	https://openalex.org/A5061761089
authorships[24].author.orcid	https://orcid.org/0000-0003-3590-7916
authorships[24].author.display_name	Pinuccia Valagussa
authorships[24].author_position	middle
authorships[24].raw_author_name	Pinuccia Valagussa
authorships[24].is_corresponding	False
authorships[25].author.id	https://openalex.org/A5088697304
authorships[25].author.orcid	https://orcid.org/0000-0003-1882-7068
authorships[25].author.display_name	Giuseppe Viale
authorships[25].author_position	middle
authorships[25].raw_author_name	Giuseppe Viale
authorships[25].is_corresponding	False
authorships[26].author.id	https://openalex.org/A5058537459
authorships[26].author.orcid	https://orcid.org/0000-0002-2372-9625
authorships[26].author.display_name	Luca Gianni
authorships[26].author_position	middle
authorships[26].raw_author_name	Luca Gianni
authorships[26].is_corresponding	False
authorships[27].author.id	https://openalex.org/A5050476736
authorships[27].author.orcid	https://orcid.org/0000-0002-6790-6267
authorships[27].author.display_name	Giampaolo Bianchini
authorships[27].author_position	last
authorships[27].raw_author_name	Giampaolo Bianchini
authorships[27].is_corresponding	False
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434263/1/files/50134549.pdf
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10158
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9986000061035156
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2730
primary_topic.subfield.display_name	Oncology
primary_topic.display_name	Cancer Immunotherapy and Biomarkers
related_works	https://openalex.org/W4248636606, https://openalex.org/W3024972238, https://openalex.org/W4401573389, https://openalex.org/W4388045576, https://openalex.org/W2186633408, https://openalex.org/W2788599721, https://openalex.org/W2706973099, https://openalex.org/W2903279629, https://openalex.org/W3142396241, https://openalex.org/W4402558537
cited_by_count	0
locations_count	2
best_oa_location.id	doi:10.1158/1078-0432.27434263
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434263/1/files/50134549.pdf
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.27434263
primary_location.id	doi:10.1158/1078-0432.27434263
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S4_from_The_Immune-Related_27-Gene_Signature_DetermaIO_Predicts_Response_to_Neoadjuvant_Atezolizumab_plus_Chemotherapy_in_Triple-Negative_Breast_Cancer/27434263/1/files/50134549.pdf
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.27434263
publication_date	2024-11-01
publication_year	2024
referenced_works_count	0
abstract_inverted_index.4.	2
abstract_inverted_index.A)	7
abstract_inverted_index.B)	25
abstract_inverted_index.C)	37
abstract_inverted_index.D)	50
abstract_inverted_index.E)	66
abstract_inverted_index.IO	5, 28, 41, 54, 82
abstract_inverted_index.by	21, 40, 47, 56, 63, 84
abstract_inverted_index.in	14
abstract_inverted_index.of	9, 52
abstract_inverted_index.on	90
abstract_inverted_index.or	34, 80
abstract_inverted_index.IO+	10
abstract_inverted_index.and	11, 20, 30, 43, 59, 95
abstract_inverted_index.arm	23, 58
abstract_inverted_index.pCR	38, 60
abstract_inverted_index.the	15
abstract_inverted_index.arm.	45, 86
abstract_inverted_index.from	71
abstract_inverted_index.rate	39
abstract_inverted_index.were	88
abstract_inverted_index.with	92
abstract_inverted_index.(AIC)	70
abstract_inverted_index.IO−	12
abstract_inverted_index.PD-L1	31
abstract_inverted_index.sTILs	35
abstract_inverted_index.score	55
abstract_inverted_index.using	77
abstract_inverted_index.(left)	19, 33
abstract_inverted_index.Akaike	67
abstract_inverted_index.Figure	1
abstract_inverted_index.models	75
abstract_inverted_index.score.	6
abstract_inverted_index.scores	83
abstract_inverted_index.status	32
abstract_inverted_index.NeoTRIP	17
abstract_inverted_index.RNA-Seq	4, 81, 96
abstract_inverted_index.RT-qPCR	79, 94
abstract_inverted_index.between	27
abstract_inverted_index.classes	29
abstract_inverted_index.matched	93
abstract_inverted_index.overall	16
abstract_inverted_index.status.	61
abstract_inverted_index.(right);	24, 36
abstract_inverted_index.Analyses	87
abstract_inverted_index.Baseline	3
abstract_inverted_index.P-values	46, 62
abstract_inverted_index.logistic	48, 64, 73
abstract_inverted_index.obtained	76
abstract_inverted_index.patients	13, 91
abstract_inverted_index.Frequency	8
abstract_inverted_index.criterion	69
abstract_inverted_index.performed	89
abstract_inverted_index.treatment	22, 44, 57, 85
abstract_inverted_index.continuous	53
abstract_inverted_index.population	18
abstract_inverted_index.regression	74
abstract_inverted_index.univariate	72
abstract_inverted_index.Association	26
abstract_inverted_index.categorical	78
abstract_inverted_index.information	68
abstract_inverted_index.regression.	49, 65
abstract_inverted_index.Distribution	51
abstract_inverted_index.classification	42
abstract_inverted_index.data.</p>	97
abstract_inverted_index.<p>Supplementary	0
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	28
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.8399999737739563
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.38104924
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False